Association of statin use with cataracts: a propensity score-matched analysis
- PMID: 24052188
- DOI: 10.1001/jamaophthalmol.2013.4575
Association of statin use with cataracts: a propensity score-matched analysis
Abstract
Importance: Cataracts are a main cause of low vision; with the growing elderly population, the incidence of cataracts is likely to increase. Investigators have previously hypothesized that statin antioxidant effects may slow the natural aging process of the lens.
Objective: To compare the risks for development of cataracts between statin users and nonusers.
Design: A propensity score-matched cohort analysis using retrospective data from October 1, 2003, to March 1, 2010. A propensity score-matched cohort of statin users and nonusers was created using 44 variables.
Setting: Database of a military health care system.
Participants: Based on medication fills during fiscal year 2005, patients were divided into 2 groups: (1) statin users (received at least a 90-day supply of statin) and (2) nonusers (never received a statin throughout the study). Among 46,249 patients meeting study criteria, we identified 13,626 statin users and 32,623 nonusers.
Exposure: Use of statin therapy for more than 90 days.
Main outcomes and measures: Primary analysis examined the risks for cataract in the propensity score-matched cohort. Secondary analyses examined the risks for cataract in patients with no comorbidities according to the Charlson Comorbidity Index (patients with no Charlson comorbidity). A sensitivity analysis was conducted to repeat the secondary analysis in patients taking statins for durations of 2, 4, and 6 years.
Results: For our primary analysis, we matched 6972 pairs of statin users and nonusers. The risk for cataract was higher among statin users in comparison with nonusers in the propensity score-matched cohort (odds ratio, 1.09; 95% CI, 1.02-1.17). In secondary analyses, after adjusting for identified confounders, the incidence of cataract was higher in statin users in comparison with nonusers (odds ratio, 1.27; 95% CI, 1.15-1.40). Sensitivity analysis confirmed this relationship.
Conclusions and relevance: The risk for cataract is increased among statin users as compared with nonusers. The risk-benefit ratio of statin use, specifically for primary prevention, should be carefully weighed, and further studies are warranted.
Comment in
-
Statins and cataract.JAMA Ophthalmol. 2014 Mar;132(3):362-3. doi: 10.1001/jamaophthalmol.2013.8265. JAMA Ophthalmol. 2014. PMID: 24626831 No abstract available.
-
Statin use and cataract.JAMA Ophthalmol. 2014 Mar;132(3):363-4. doi: 10.1001/jamaophthalmol.2013.8263. JAMA Ophthalmol. 2014. PMID: 24626832 No abstract available.
-
Statins and cataract--reply.JAMA Ophthalmol. 2014 Mar;132(3):363. doi: 10.1001/jamaophthalmol.2013.8267. JAMA Ophthalmol. 2014. PMID: 24626833 No abstract available.
-
Statin use and cataract--reply.JAMA Ophthalmol. 2014 Mar;132(3):364-5. doi: 10.1001/jamaophthalmol.2014.40. JAMA Ophthalmol. 2014. PMID: 24626834 No abstract available.
-
Cataracts and statin use: cause and effect not confirmed.JAMA Ophthalmol. 2014 Mar;132(3):365. doi: 10.1001/jamaophthalmol.2014.23. JAMA Ophthalmol. 2014. PMID: 24626835 No abstract available.
-
Cataracts and statin use--reply.JAMA Ophthalmol. 2014 Mar;132(3):365-6. doi: 10.1001/jamaophthalmol.2014.75. JAMA Ophthalmol. 2014. PMID: 24626836 No abstract available.
-
Statin use and cataracts.JAMA Ophthalmol. 2014 Mar;132(3):366-7. doi: 10.1001/jamaophthalmol.2014.225. JAMA Ophthalmol. 2014. PMID: 24626837 No abstract available.
Similar articles
-
Frequency of development of connective tissue disease in statin-users versus nonusers.Am J Cardiol. 2013 Sep 15;112(6):883-8. doi: 10.1016/j.amjcard.2013.04.059. Epub 2013 Jun 11. Am J Cardiol. 2013. PMID: 23764243
-
Comparison of frequency of inflammatory bowel disease and noninfectious gastroenteritis among statin users versus nonusers.Am J Cardiol. 2015 May 15;115(10):1396-401. doi: 10.1016/j.amjcard.2015.02.035. Epub 2015 Feb 18. Am J Cardiol. 2015. PMID: 25784517
-
Statins and musculoskeletal conditions, arthropathies, and injuries.JAMA Intern Med. 2013 Jul 22;173(14):1-10. doi: 10.1001/jamainternmed.2013.6184. JAMA Intern Med. 2013. PMID: 23877079
-
Statin Use and the Risk of Cataracts: A Systematic Review and Meta-Analysis.J Am Heart Assoc. 2017 Mar 20;6(3):e004180. doi: 10.1161/JAHA.116.004180. J Am Heart Assoc. 2017. PMID: 28320745 Free PMC article. Review.
-
Statins and Cataracts--a visual insight.Curr Atheroscler Rep. 2015;17(2):477. doi: 10.1007/s11883-014-0477-2. Curr Atheroscler Rep. 2015. PMID: 25488134 Review.
Cited by
-
PCSK9 Inhibitor: Safe Alternative to Fill the Treatment Gap in Statin-Limited Conditions?Rev Cardiovasc Med. 2022 Nov 9;23(11):380. doi: 10.31083/j.rcm2311380. eCollection 2022 Nov. Rev Cardiovasc Med. 2022. PMID: 39076187 Free PMC article. Review.
-
Lanosterol regulates abnormal amyloid accumulation in LECs through the mediation of cholesterol pathway metabolism.Biochem Biophys Rep. 2024 Mar 11;38:101679. doi: 10.1016/j.bbrep.2024.101679. eCollection 2024 Jul. Biochem Biophys Rep. 2024. PMID: 38501050 Free PMC article.
-
Rosuvastatin versus atorvastatin treatment in adults with coronary artery disease: secondary analysis of the randomised LODESTAR trial.BMJ. 2023 Oct 18;383:e075837. doi: 10.1136/bmj-2023-075837. BMJ. 2023. PMID: 37852649 Free PMC article. Clinical Trial.
-
Effect of cholesterol variability on the incidence of cataract, dementia, and osteoporosis: A study using a common data model.Medicine (Baltimore). 2023 Oct 13;102(41):e35548. doi: 10.1097/MD.0000000000035548. Medicine (Baltimore). 2023. PMID: 37832124 Free PMC article.
-
The Effect of Statins on Ocular Disorders: A Systematic Review of Randomized Controlled Trials.Pharmaceuticals (Basel). 2023 May 7;16(5):711. doi: 10.3390/ph16050711. Pharmaceuticals (Basel). 2023. PMID: 37242493 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
